NCT06347705

A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer

Phase II Study Evaluating the Effects of Single Site Intratumoral Injections of Anti-CD40 Agonist Antibody (2141-V11) Given as Monotherapy Prior to Radical Prostatectomy to Men With Intermediate Risk Disease and in Combination With Androgen Deprivation Therapy for Those With High Risk Localized and Low Volume Metastatic Disease

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 57 (estimated)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to see whether combining 2141-V11 with various standard treatments is an effective treatment approach for prostate cancer. 2141-V11 works by activating the immune system to find and kill cancer cells. Researchers will look at whether this treatment approach is able to completely get rid of cancer in participants, and they will check for the presence of minimal residual disease (MRD) in participants. MRD is a small number of cancer cells that can be detected in the body after treatment.

Conditions

• Prostate Cancer

Interventions

Type	Name	Description
BIOLOGICAL	2141-V11 Antibody	2141-V11 Antibody: Intratumor injection

Timeline

• Start date: 2024-03-28
• Primary completion: 2029-03-28
• Completion: 2029-03-28
• First posted: 2024-04-04
• Last updated: 2026-04-16

Locations

7 sites across 1 country: United States

Regulatory

• FDA-regulated drug study